ArticleHIV medicine2026
Hierarchical analysis of unsuccessful tuberculosis treatment among people living with HIV in Brazil using nationwide surveillance data.
Article in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPeople with tuberculosis-HIV coinfection face multiple barriers to effective treatment, including social vulnerability, stigma and limited access to healthcare. This study examined factors associated with loss to follow-up and death among individuals with tuberculosis-HIV in Brazil.
methodsWe conducted a longitudinal study using a nationally linked database from surveillance systems. Poisson regression models with robust variance were applied to identify factors associated with unfavourable outcomes, guided by a theoretical-conceptual hierarchical framework.
resultsWe analysed data from 54 516 individuals. The median time to loss to treatment follow-up was 115 days, with a cumulative proportion of 29.56%. Among the most consistent predictors of loss to follow-up were homelessness (relative risk, RR 1.18; 95% confidence interval, 95% CI 1.16-1.19), tuberculosis retreatment (RR 1.16; 95% CI 1.15-1.17) and drug use (RR 1.15; 95% CI 1.14-1.16), whereas antiretroviral therapy use (RR 0.95; 95% CI 0.95-0.96) showed a negative association. The median time to death during tuberculosis treatment was 27 days, with a cumulative proportion of 27.54%. Higher risk of death was observed among individuals with CD4 counts <350 cells/mm
conclusionKey social, clinical and programmatic factors were associated with loss to follow-up and death during tuberculosis treatment among people with HIV. Addressing these vulnerabilities is essential to improving treatment outcomes and advancing progress towards the 2030 targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.